Results 161 to 170 of about 3,923 (195)
Some of the next articles are maybe not open access.
Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection
Expert Opinion on Drug Metabolism & Toxicology, 2018Meropenem/vaborbactam (M/V) represents the first carbapenem and β-lactamase inhibitor combination approved for treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. Vaborbactam is a novel boronic acid, β-lactamase inhibitor with a high affinity for serine β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC ...
Rodrigo M, Burgos +3 more
openaire +2 more sources
A Brief Review of a New Antibiotic: Meropenem-vaborbactam
The Senior Care Pharmacist, 2019Meropenem-vaborbactam is a newly approved antibiotic for complex urinary tract infections and to treat carbapenem-resistant Enterobacteriaceae infections. Its advantage over meropenem is the betalactamase inhibitor which slows bacterial resistance. This medication has been studied in numerous countries and has relatively few side effects.
openaire +2 more sources
Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination
Annals of Pharmacotherapy, 2018Objective: To review the pharmacology, spectrum of activity, pharmacokinetics, pharmacodynamics, safety, efficacy, administration, and considerations for clinical use of meropenem/vaborbactam (M/V). Data Sources: A literature search using PubMed and clinicaltrials.gov (June 2013 to December 2017) was conducted using the search terms meropenem ...
Jonathan C, Cho +3 more
openaire +2 more sources
Meropenem / Meropenem-vaborbactam
2017Meropenem is a broad-spectrum parenteral carbapenem with antimicrobial activity against a wide range of Gramnegative and Gram-positive bacteria, including anaerobes. As a consequence of emerging multidrug resistance, especially in Gram-negative organisms, the clinical reliance on meropenem and other carbapenems increased after their introduction ...
Peleg, A. Y., Harris, P.
openaire +2 more sources
Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection
The Journal of Pediatric Pharmacology and TherapeuticsMeropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract
Ugene, Sano +3 more
openaire +2 more sources

